BioNTech and Pfizer announce $225M shingles vaccine project, offering mRNA challenger to GlaxoSmithKline's Shingrix
One of the biggest storylines of biotech’s next half-decade will be where Moderna, BioNTech and their growing list of rivals push the mRNA technology that’s already changed the world.
BioNTech and Pfizer gave part of the answer Wednesday, announcing a new partnership to co-develop an mRNA-based shingles vaccine. The candidate will be ready for early-stage trials in the second half of 2022, the companies said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.